Renalytix Past Earnings Performance

Past criteria checks 0/6

Renalytix's earnings have been declining at an average annual rate of -25.3%, while the Healthcare Services industry saw earnings growing at 6.8% annually. Revenues have been growing at an average rate of 36.6% per year.

Key information

-25.3%

Earnings growth rate

-19.1%

EPS growth rate

Healthcare Services Industry Growth12.5%
Revenue growth rate36.6%
Return on equityn/a
Net Margin-1,191.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Renalytix makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

AIM:RENX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242-28177
30 Jun 242-33209
31 Mar 242-372211
31 Dec 232-422513
30 Sep 233-442613
30 Jun 233-462914
31 Mar 234-403314
31 Dec 224-423614
30 Sep 223-474014
30 Jun 223-454015
31 Mar 223-503615
31 Dec 212-443114
30 Sep 212-382712
30 Jun 211-352310
31 Mar 211-28188
31 Dec 200-20119
30 Sep 200-1695
30 Jun 200-1065
31 Mar 2002861
31 Dec 190-860
30 Sep 190-531
30 Jun 190-4234

Quality Earnings: RENX is currently unprofitable.

Growing Profit Margin: RENX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RENX is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.

Accelerating Growth: Unable to compare RENX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RENX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.6%).


Return on Equity

High ROE: RENX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:37
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Renalytix Plc is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Mark MassaroBTIG
David WestenbergGuggenheim Securities, LLC